Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R F Storey

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Thrombosis and Haemostasis|November 2, 1999
A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologiesR F Storey, J A May, R G Wilcox, et al.
Thrombosis and Haemostasis|May 13, 2014
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' valueL Wallentin, A Himmelmann, R F Storey, et al.
International Journal of Clinical Practice|April 2, 2009
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trialS Husted, R A Harrington, C P Cannon, et al.
Journal of Thrombosis and Haemostasis : JTH|May 25, 2010
Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrelH M Judge, S B Patil, R J Buckland, et al.
British Journal of Haematology|October 29, 2000
The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activityR F Storey, H M Sanderson, A E White, et al.
Platelets|October 1, 2005
PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapyS M G Smith, H M Judge, G Peters, et al.
Heart (British Cardiac Society)|September 18, 2014
Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapyM Janzon, S James, C P Cannon, et al.
Journal of Thrombosis and Haemostasis : JTH|June 29, 2011
Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responsesR F Storey, K P Bliden, R Ecob, et al.
Circulation|December 24, 2008
Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosisD J W Evans, L E Jackman, J Chamberlain, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 31, 2023
Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational studyM P Bonaca, E Lesén, E Giannitsis, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Thrombosis and Haemostasis|November 2, 1999
A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologiesR F Storey, J A May, R G Wilcox, et al.
Thrombosis and Haemostasis|May 13, 2014
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' valueL Wallentin, A Himmelmann, R F Storey, et al.
International Journal of Clinical Practice|April 2, 2009
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trialS Husted, R A Harrington, C P Cannon, et al.
Journal of Thrombosis and Haemostasis : JTH|May 25, 2010
Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrelH M Judge, S B Patil, R J Buckland, et al.
British Journal of Haematology|October 29, 2000
The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activityR F Storey, H M Sanderson, A E White, et al.
Platelets|October 1, 2005
PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapyS M G Smith, H M Judge, G Peters, et al.
Heart (British Cardiac Society)|September 18, 2014
Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapyM Janzon, S James, C P Cannon, et al.
Journal of Thrombosis and Haemostasis : JTH|June 29, 2011
Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responsesR F Storey, K P Bliden, R Ecob, et al.
Circulation|December 24, 2008
Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosisD J W Evans, L E Jackman, J Chamberlain, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 31, 2023
Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational studyM P Bonaca, E Lesén, E Giannitsis, et al.
Pageof 3